| Previous Close | 175.79 |
| Open | 176.16 |
| Bid | 0.00 x 1400 |
| Ask | 0.00 x 900 |
| Day's Range | 174.70 - 178.08 |
| 52 Week Range | 151.80 - 195.81 |
| Volume | 1,040,788 |
| Avg. Volume | 1,163,206 |
| Market Cap | 45.172B |
| Beta (3Y Monthly) | 1.18 |
| PE Ratio (TTM) | 21.25 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Vertex Pharmaceuticals Incorporated (VRTX) today announced the U.S. Food and Drug Administration (FDA) approved SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for use in children with cystic fibrosis ages 6 through 11 years who have two copies of the F508del-CFTR mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to SYMDEKO. It was previously approved by the FDA for use in patients with cystic fibrosis 12 years and older with two copies of the F508del mutation or one copy of a responsive mutation in the U.S. An additional dosage strength of SYMDEKO tablets is now available (tezacaftor 50 mg/ivacaftor 75 mg and ivacaftor 75 mg) in connection with this approval.
Vertex Pharmaceuticals Incorporated (VRTX) today announced that the company is enhancing its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) by expanding its collaboration with CRISPR Therapeutics and acquiring Exonics Therapeutics.
Vertex Pharmaceuticals Incorporated (VRTX) today announced that data from six scientific abstracts from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 42nd European Cystic Fibrosis Conference, taking place June 5-8, 2019 in Liverpool, UK. These abstracts include data being presented from the ongoing Phase 3 ARRIVAL study of the pharmacokinetics (PK) and safety of KALYDECO® (ivacaftor) in a cohort of patients 6 to
-Mean absolute improvement in ppFEV1 of 14.3 percentage points from baseline through week 24 of treatment compared to placebo in patients with one F508del m
Vertex Pharmaceuticals Incorporated (VRTX) and Kymera Therapeutics today announced that the two companies have entered into a four-year strategic research and development collaboration to advance small molecule protein degraders against multiple targets. The collaboration will leverage Kymera’s expertise in targeted protein degradation and its proprietary Pegasus™ drug discovery platform and Vertex’s scientific, clinical, and regulatory capabilities to accelerate the development of first-in-class medicines for people with serious diseases.
- First-quarter 2019 product revenues of $857 million, a 34% increase compared to $638 million in 2018-
Vertex Pharmaceuticals Incorporated (VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO® (ivacaftor) for use in children with cystic fibrosis (CF) ages six months to less than 12 months who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to KALYDECO based on clinical and/or in vitro assay data. KALYDECO is already approved in the U.S., Canada and EU for the treatment of CF in patients ages 12 months and older.
CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals Incorporated (VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the treatment of transfusion-dependent beta thalassemia (TDT). The FDA’s Fast Track program is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill unmet medical needs. A drug granted Fast Track Designation may be eligible for several benefits, including more frequent meetings and communications with the FDA and, if relevant criteria are met, the potential for Accelerated Approval, Priority Review or Rolling Review of a Biologics License Application (BLA).
Vertex Pharmaceuticals Incorporated (VRTX) will report its first quarter 2019 financial results on Tuesday, April 30, 2019 after the financial markets close. An archived webcast will be available on the company's website. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Vertex Pharmaceuticals Incorporated (VRTX) today announced the appointment of Charles (Charlie) Wagner as Executive Vice President and Chief Financial Officer (CFO), effective April 10, 2019. Mr. Wagner will report directly to Vertex Chairman, President and Chief Executive Officer Jeffrey Leiden, M.D., Ph.D., and oversee the finance, internal audit, investor relations, and global security and facilities functions. Mr. Wagner joins Vertex with deep corporate finance and health care experience, including more than a decade in public and private company CFO roles.
Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration (TGA) of Australia has granted registration to SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence. Mutations in the CFTR gene that produce CFTR protein responsive to SYMDEKO® include F508del and mutations in which the CFTR protein shows residual function: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, 3849+10kbC→T, E56K, R74W, D110E, D110H, E193K, E831X, F1052V, K1060T, A1067T, F1074L and D1270N.
-Mean absolute improvement in ppFEV1 of 13.8 percentage points from baseline at week 4 in people with one F508del mutation and one minimal function mutation compared to plac
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals Incorporated (VRTX) today reviewed recent progress in the clinical development programs for CTX001, an investigational, autologous, CRISPR/Cas9 gene-edited hematopoietic stem cell therapy being evaluated for patients suffering from severe hemoglobinopathies. The companies announced that the first patient has been treated with CTX001 in a Phase 1/2 clinical study of patients with transfusion-dependent beta thalassemia (TDT), marking the first company-sponsored use of a CRISPR/Cas9 therapy in a clinical trial.
Vertex Pharmaceuticals Incorporated (VRTX) today announced that Lloyd Carney has been appointed to its board of directors as an independent director. Mr. Carney is a prominent technology executive with experience leading innovative, high-growth organizations. The addition of Mr. Carney brings Vertex’s board of directors to 10 members.
Vertex Pharmaceuticals Incorporated (VRTX) today announced the results of a Phase 3 study conducted in Europe and Australia of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis (CF) who have either two copies of the F508del mutation or one copy of the F508del mutation and one residual function mutation. The study met its primary endpoint of absolute change in lung clearance index (LCI2.5) through 8 weeks of treatment, demonstrating a statistically significant improvement in LCI2.5 among patients treated with tezacaftor/ivacaftor.
- Full-year 2018 CF product revenues of $3.04 billion, a 40% increase compared to $2.17 billion in 2017; fourth-quarter 2018 CF product revenues of $868 million -
NEW YORK, NY / ACCESSWIRE / February 5, 2019 / Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February ...
NEW YORK, Jan. 31, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Vertex Pharmaceuticals Incorporated (VRTX) today announced that Health Canada has granted Market Authorization for KALYDECO® (ivacaftor) to include use in children with cystic fibrosis (CF) ages 12 to
DARMSTADT, Germany , January 24, 2019 /PRNewswire/ -- Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease ...
DARMSTADT, Germany , Jan. 24, 2019 /CNW/ - Merck, a leading science and technology company, today announced that it has entered into an exclusive licensing agreement with Vertex Pharmaceuticals Incorporated, Boston , USA (VRTX), for two DNA-dependent protein kinase (DNA-PK) inhibitors - M9831 (formerly known as VX-984) and an additional pre-clinical compound - in the field of gene editing for six specific genetic disease indications. Merck will receive an upfront payment in addition to milestones and royalties on future net sales and retains the rights to both assets in all other disease areas, including oncology, with the ability to develop both these compounds in-house, or to license them to future partners in the gene editing field.
Vertex Pharmaceuticals Incorporated (VRTX) today announced that Ian Smith has been terminated as Chief Operating Officer and interim Chief Financial Officer (CFO) effective immediately. Mr. Smith’s termination is the result of personal behavior that violated Vertex’s Code of Conduct and values and is unrelated to the Company’s financial and business performance. The Company and the Board made this determination following a prompt and comprehensive investigation conducted with the assistance of independent external counsel, WilmerHale.
Vertex Pharmaceuticals Incorporated (VRTX) will report its full year and fourth quarter 2018 financial results on Tuesday, February 5, 2019 after the financial markets close. An archived webcast will be available on the company's website. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. The label update is based on data from a Phase 3 open-label safety study in 60 patients that showed treatment with lumacaftor/ivacaftor was generally well tolerated for 24 weeks, with a safety profile in these pediatric patients generally consistent with that in patients aged 6 years and older.